SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization.

SEOUL, South Korea , Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and oncology worldwide, today announced the establishment of Mentis Care, Inc., a joint venture with a leading Brazil-based pharmaceutical company, Eurofarma, with presence in 24 countries, including North America, Latin America and Africa, to commercialize an AI-based epilepsy management platform. The company hosted a launching ceremony on October 20 (EDT) in Toronto, Canada, to celebrate its full-scale expansion into

See Full Page